Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options
https://doi.org/10.21518/2079-701X-2021-10-86-93
Abstract
Epilepsy is a common chronic neurological disease. The problems of people with epilepsy go well beyond epileptic seizures. Comorbidities in epilepsy are very common and often cause more problems to the patients than the seizures themselves. Although seizures are the most prominent clinical presentation of epilepsy, people with epilepsy are exposed to risk of not only seizures, but also of many health problems. Both children and adults with epilepsy often complain of memory impairment. It is commonly believed that cognitive dysfunction in epilepsy is multifactorial. The components that deteriorate cognitive functions include active seizures and especially generalized tonic-clonic seizures, traumatic brain injuries, structural epilepsy, and drug therapy. Cognitive dysfunction is very often present as far back as during the onset of epilepsy. The cognitive dysfunction detected in patients with epilepsy depend on the localization of the epileptic focus, the frequency and type of epileptic seizures, and changes in the interictal electroencephalogram. Seizures can be controlled with antiepileptic drugs in most patients with epilepsy. Therapy of cognitive dysfunction in patients with epilepsy presents significant difficulties, as there is no evidence of the efficacy of various drugs in cognitive disorders. The article presents a new Russian antiepileptic drug based on phenosanic acid as part of combination therapy in patients with partial epileptic seizures with or without secondary generalization, which can improve cognitive functions in patients with epilepsy.
About the Authors
N. V. Pizova
Yaroslavl State Medical University
Russian Federation
Russian Federation
Nataliia V. Pizova, Dr. Sci. (Med.), Professor, Professor of the Department of Nervous Diseases with Medical Genetics and Neurosurgery.
5, Revolutsionnaya St., Yaroslavl, 150000
A. V. Pizov
Yaroslavl State Pedagogical University named after K.D. Ushinsky
Russian Federation
Russian Federation
Aleksandr V. Pizov, Cand. Sci. (Biol.), Associate Professor of the Department of Medicine.
108/1, Republikanskaya St., Yaroslavl, 150000
References
1. Fisher R.S., Acevedo C., Arzimanoglou A., Bogacz A., Cross J.H., Elger C.E. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia. 2014;55(4):475-482. https://doi.org/10.1111/epi.12550.
2. Thijs R.D., Surges R., O'Brien TJ., Sander J.W. Epilepsy in adults. Lancet. 2019;393(10172):689-701. https://doi.org/10.1016/S0140-6736(18)32596-0.
3. Helmstaedter C., Witt J.A. Chapter 28 - Clinical neuropsychology in epilepsy: theoretical and practical issues. Handb Clin Neurol. 2012;107: 437-459. https://doi.org/10.1016/B978-0-444-52898-8.00036-7.
4. Anthony J.C., Eaton W.W., Henderson A.S. Looking to the future in psychiatric epidemiology. Epidemiol Rev. 1995;17(1):240-242. https://doi.org/10.1093/oxfordjournals.epirev.a036182.
5. Helmstaedter C., Witt J.A. Epilepsy and cognition - A bidirectional relationship? Seizure. 2017;49:83-89. https://doi.org/10.1016/j.seizure.2017.02.017.
6. Wirrell E.C., Camfield C.S., Camfield P.R., Dooley J.M., Gordon K.E., Smith B. Long-term psychosocial outcome in typical absence epilepsy. Sometimes a wolf in sheeps' clothing. Arch Pediatr Adolesc Med. 1997;151(2):152-158. https://doi.org/10.1001/archpedi.1997.02170390042008.
7. Braun K.P. Preventing cognitive impairment in children with epilepsy. Curr Opin Neurol. 2017;30(2):140-147. https://doi.org/10.1097/WCO.0000000000000424.
8. Witt J.A., Helmstaedter C. Cognition in the early stages of adult epilepsy. Seizure. 2015;26:65-68. https://doi.org/10.1016/j.seizure.2015.01.018.
9. Pulliainen V., Kuikka P, Jokelainen M. Motor and cognitive functions in newly diagnosed adult seizure patients before antiepileptic medication. Acta Neurol Scand. 2000;101(2):73-78. https://doi.org/10.1034/j.1600-0404.2000.101002073.x.
10. Witt J.A., Helmstaedter C. Should cognition be screened in new-onset epilepsies? A study in 247 untreated patients. J Neurol. 2012;259(8): 1727-1731. https://doi.org/10.1007/s00415-012-6526-2.
11. Wilson SJ., Baxendale S., Barr W., Hamed S., Langfitt J., Samson S. et al. In response: Indications and expectations for neuropsychological assessment in routine epilepsy care: Report of the ILAE Neuropsychology Task Force, Diagnostic Methods Commission, 2013-2017. Epilepsia. 2015;56(8):1316-1317. https://doi.org/10.1111/epi.13055.
12. Elger C.E., Helmstaedter C., Kurthen M. Chronic epilepsy and cognition. Lancet Neurol. 2004;3(11):663-672. https://doi.org/10.1016/S1474-4422(04)00906-8.
13. Loughman A., Bowden S.C., D'Souza WJ. A comprehensive assessment of cognitive function in the common genetic generalized epilepsy syndromes. Eur J Neurol. 2017;24(3):453-460. https://doi.org/10.1111/ene.13232.
14. Yang H.-L., Chan P.-T., Chang P.-C., Chiu H.-L., Sheen Hsiao S.-T., Chu H., Chou K.-R. Memory-focused interventions for people with cognitive disorders: A systematic review and meta-analysis of randomized controlled studies. Int J Nurs Stud. 2018;78:44-51. https://doi.org/10.1016/j.ijnurs-tu.2017.08.005.
15. Berg A.T. Epilepsy, cognition, and behavior: the clinical picture. Epilepsia. 2011;52(1 Suppl.):7-12. https://doi.org/10.1111/j.1528-1167.2010.02905.x.
16. Vishnoi S., Raisuddin S., Parvez S. Glutamate excitotoxicity and oxidative stress in epilepsy: modulatory role of melatonin. J Environ Pathol Toxicol Oncol. 2016;35(4):365-374. https://doi.org/10.1615/JEnvironPathol ToxicolOncol.2016016399.
17. Zavadenko N.N., Kemalov A.I. Consequences of severe traumatic brain injury in children and their treatment. Voprosy sovremennoj pedi-atrii = Current Pediatrics. 2006;5(4):14-21. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/750.
18. Zavadenko N.N., Guzilova L.S., Iznak A.F., Iznak Ye.V. Consequences of severe craniocerebral injury in adolescents: clinical features and methods of treatment. Voprosy sovremennoj pediatrii = Current Pediatrics. 2010;9(4):57-67. (In Russ.) Available at: https://vsp.spr-journal.ru/jour/article/view/921.
19. Cansu A., Serdaroglu A., Yuksel D., Dogan V., Ozkan S., Hirfanoglu T. et al. Prevalence of some risk factors in children with epilepsy compared to their controls. Seizure. 2007;16(4):338-344. https://doi.org/10.1016/j.sei-zure.2007.02.003.
20. Appleton R.E., Demellweek C. Post-traumatic epilepsy in children requiring inpatient rehabilitation following head injury. J Neurol Neurosurg Psychiatry. 2002;72(5):669-672. https://doi.org/10.1136/jnnp.72.5.669.
21. Tagliaferri F., Compagnone C., Korsic M., Servadei F., Kraus J. A systematic review of brain injury epidemiology in Europe. Acta Neurochir (Wien). 2006;148(3):255-268. https://doi.org/10.1007/s00701-005-0651-y.
22. Christensen J. The Epidemiology of posttraumatic epilepsy. Semin Neurol. 2015;35(3):218-222. https://doi.org/10.1055/s-0035-1552923.
23. Hauser W.A., Annegers J.F., Kurland L.T. Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota: 1935-1984. Epilepsia. 1993;34(3):453-458. https://doi.org/10.111Vj.1528-1157.1993. tb02586.x.
24. Lowenstein D.H. Epilepsy after head injury: an overview. Epilepsia. 2009;50(2 Suppl.):4-9. https://doi.org/10.1111/j.1528-1167.2008.02004.x.
25. Horvath A., Szucs A., Barcs G., Noebels J.L., Kamondi A. Epileptic seizures in Alzheimer disease. Alzheimer Dis Assoc Disord. 2016;30(2):186-192. https://doi.org/10.1097/WAD.0000000000000134.
26. Zarea A., Charbonnier C., Rovelet-Lecrux A., Nicolas G., Rousseau S., Borden A. et al. PHRC GMAJ Collaborators. Seizures in dominantly inherited Alzheimer disease. Neurology. 2016;87(9):912-919. https://doi.org/10.1212/WNL.0000000000003048.
27. Beagle AJ., Darwish S.M., Ranasinghe K.G., La A.L., Karageorgiou E., Vossel K.A. Relative incidence of seizures and myoclonus in Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia. J Alzheimers Dis. 2017;60(1):211-223. https://doi.org/10.3233/JAD-170031.
28. Subota A., Pham T., Jette N., Sauro K., Lorenzetti D., Holroyd-Leduc J. The association between dementia and epilepsy: a systematic review and meta-analysis. Epilepsia. 2017;58(6):962-972. https://doi.org/10.1111/epi.13744.
29. Ogunrin O., Adamolekun B., Ogunniyi A.O., Aldenkamp A.P. Cognitive function in Nigerians with newly diagnosed epilepsy. Can J Neurol Sci. 2000;27(2): 148-151. Available at: https://pubmed.ncbi.nlm.nih.gov/10830349.
30. Sen A., Capelli V., Husain M. Cognition and dementia in older patients with epilepsy. Brain. 2018;141(6):1592-1608. https://doi.org/10.1093/brain/awy022.
31. O'Muircheartaigh J., Richardson M.P. Epilepsy and the frontal lobes. Cortex. 2012;48(2):144-155. https://doi.org/10.1016/j.cortex.2011.11.012.
32. Saling M.M. Verbal memory in mesial temporal lobe epilepsy: beyond material specificity. Brain. 2009;132(3):570-582. https://doi.org/10.1093/brain/awp012.
33. Bell B., Lin JJ., Seidenberg M., Hermann B. The neurobiology of cognitive disorders in temporal lobe epilepsy. Nat Rev Neurol. 2011;7(3):154-164. https://doi.org/10.1038/nrneurol.2011.3.
34. Helmstaedter C., Kurthen M., Lux S., Reuber M., Elger C.E. Chronic epilepsy and cognition: a longitudinal study in temporal lobe epilepsy. Ann Neurol. 2003;54(4):425-432. https://doi.org/10.1002/ana.10692.
35. Hermann B.P., Seidenberg M., Dow C., Jones J., Rutecki P, Bhattacharya A., Bell B. Cognitive prognosis in chronic temporal lobe epilepsy. Ann Neurol. 2006;60(1):80-87. https://doi.org/10.1002/ana.20872.
36. Risse G.L. Cognitive outcomes in patients with frontal lobe epilepsy. Epilepsia. 2006;47(2 Suppl.):87-89. https://doi.org/10.1111/j.1528-1167.2006.00699.x.
37. Helmstaedter C., Pohl C., Elger C.E. Relations between verbal and nonverbal memory performance: evidence of confounding effects particularly in patients with right temporal lobe epilepsy. Cortex. 1995;31(2):345-355. https://doi.org/10.1016/s0010-9452(13)80367-x.
38. Luerding R., Boesebeck F., Ebner A. Cognitive changes after epilepsy surgery in the posterior cortex. J Neurol Neurosurg Psychiatry. 2004;75(4): 583-587. https://doi.org/10.1136/jnnp.2003.014746.
39. Black L.C., Schefft B.K., Howe S.R., Szaflarski J.P., Yeh H.S., Privitera M.D. The effect of seizures on working memory and executive functioning performance. Epilepsy Behav. 2010;17(3):412-419. https://doi.org/10.1016/j.yebeh.2010.01.006.
40. Holmes G.L. Cognitive impairment in epilepsy: The role of network abnormalities. Epileptic Disord. 2015;17(2):101-116. https://doi.org/10.1684/epd.2015.0739.
41. Taylor J., Baker G.A. Newly diagnosed epilepsy: Cognitive outcome at 5 years. Epilepsy Behav. 2010;18(4):397-403. https://doi.org/10.1016/j.yebeh.2010.05.007.
42. Aikia M., Salmenpera T., Partanen K., Kalviainen R. Verbal memory in newly diagnosed patients and patients with chronic left temporal lobe epilepsy. Epilepsy Behav. 2001;2(1):20-27. https://doi.org/10.1006/ebeh.2000.0140.
43. Griffith H.R., Martin R.C., Bambara J.K., Faught E., Vogtle L.K., Marson D.C. Cognitive functioning over 3 years in community dwelling older adults with chronic partial epilepsy. Epilepsy Res. 2007;74(2-3):91-96. https://doi.org/10.1016/j.eplepsyres.2007.01.002.
44. Gul A., Ahmad H. Thought suppression predicts task switching deficits in patients with frontal lobe epilepsy. Neurosciences (Riyadh). 2015;20(2):153-158. https://doi.org/10.17712/nsj.2015.2.20140652.
45. Miller L.A., Galioto R., Tremont G., Davis J., Bryant K., Roth J. et al. Cognitive impairment in older adults with epilepsy: Characterization and risk factor analysis. Epilepsy Behav. 2016;56:113-117. https://doi.org/10.1016/j.yebeh.2016.01.011.
46. Verrotti A., Carrozzino D., Milioni M., Minna M., Fulcheri M. Epilepsy and its main psychiatric comorbidities in adults and children. J Neurol Sci. 2014;343(1-2):23-29. https://doi.org/10.1016/j.jns.2014.05.043.
47. Folstein M.F., Folstein S.E., McHugh P.R. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189-198. https://doi.org/10.1016/0022-3956(75)90026-6.
48. Witt J.A., Elger C.E., Helmstaedter C. Adverse cognitive effects of antiepileptic pharmacotherapy: Each additional drug matters. Eur Neuropsycho-pharmacol. 2015;25(11):1954-1959. https://doi.org/10.1016/j.euroneu-ro.2015.07.027.
49. Park S.P Depression in patients with newly diagnosed epilepsy predicts lamotrigine-induced rash: A short-term observational study. Epilepsy Behav. 2013;28(1):88-90. https://doi.org/10.1016/j.yebeh.2013.03.028.
50. Petrovski S., Szoeke C.E., Jones N.C., Salzberg M.R., Sheffield L.J., Huggins R.M., O'Brien TJ. Neuropsychiatric symptomatology predicts seizure recurrence in newly treated patients. Neurology. 2010;75(11): 1015-1021. https://doi.org/10.1212/WNL.0b013e3181f25b16.
51. Eddy C.M., Rickards H.E., Cavanna A.E. The cognitive impact of antiepileptic drugs. Ther AdvNeurol Disord. 2011;4(6):385-407. https://doi.org/10.1177/1756285611417920.
52. Witt J.-A., Helmstaedter C. How can we overcome neuropsychological adverse effects of antiepileptic drugs? Expert Opin Pharmacother. 2017;18(6):551-554. https://doi.org/10.1080/14656566.2017.1309025.
53. Lorning D.W., Meador KJ. Cognitive and behavioral effects of epilepsy treatment. Epilepsia. 2001;42(8 Suppl.):24-32. Available at: https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1528-1157.42.s8.8.x.
54. Park S.P, Kwon S.H. Cognitive effects of antiepileptic drugs. J Clin Neurol. 2008;4(3):99-106. https://doi.org/10.3988/jcn.2008.4.3.99.
55. Lipatova L.V., Alekseeva D.V. The use of antioxidants in the complex therapy of drug-resistant epilepsy. St Peterburg: NMITs PN im. V.M Bekhtereva; 2018. 21 p. (In Russ.) Available at: https://elibrary.ru/item.asp?id=36893870.
56. Vlachos G.S., Scarmeas N. Dietary interventions in mild cognitive impairment and dementia. Dialogues Clin Neurosci. 2019;21(1):69-82. https://doi.org/10.31887/DCNS.2019.21.1/nscarmeas.
57. Ilari S., Giancotti L.A., Lauro F., Dagostino C., Gliozzi M., Malafoglia V. et al. Antioxidant modulation of sirtuin 3 during acute inflammatory pain: The ROS control. Pharmacol. Res. 2020;157:104851. https://doi.org/10.1016/j.phrs.2020.104851.
58. Lauro F., Giancotti L.A., Ilari S., Dagostino C., Gliozzi M., Morabito C. et al. Inhibition of Spinal Oxidative Stress by Bergamot Polyphenolic Fraction Attenuates the Development of Morphine Induced Tolerance and Hyperalgesia in Mice. PLoS ONE. 2016;11(5):e0156039. https://doi.org/10.1371/journal.pone.0156039.
59. Lauro F., Ilari S., Giancotti L.A., Ventura C.A., Morabito C., Gliozzi M. et al. Pharmacological effect of a new idebenone formulation in a model of carrageenan-induced inflammatory pain. Pharmacol Res. 2016;111: 767-773. https://doi.org/10.1016/j.phrs.2016.07.043.
60. Ilari S., Giancotti L.A., Lauro F., Gliozzi M., Malafoglia V., Palma E. et al. Natural Antioxidant Control of Neuropathic Pain-Exploring the Role of Mitochondrial SIRT3 Pathway. Antioxidants. 2020;9(11):1103. https://doi.org/10.3390/antiox9111103.
Review
For citations:
Pizova NV, Pizov AV. Certain risk factors for the development of cognitive impairment in persons with epilepsy and new therapeutic options. Meditsinskiy sovet = Medical Council. 2021;(10):86-93. (In Russ.) https://doi.org/10.21518/2079-701X-2021-10-86-93
Views:
534
Email this article 